For decades, cervical cancer screening has depended on a clinic visit and a pelvic exam. For millions of women, that requirement is exactly the barrier that keeps them from being screened. Roughly 25 million women in the United States are behind on or have never had cervical screening, and about 60 percent of cervical cancers occur in women who are unscreened or under-screened. The pattern is not random. It concentrates in underserved communities, among the members health plans work hardest to reach.
At-home HPV self-collection removes the barrier. A member receives a simple kit at home, collects her own sample privately, and mails it back with prepaid packaging. No appointment, no time off work, no pelvic exam. For a woman who has avoided screening for years, a kit at home replaces a visit that may never happen.
This is not a lower-quality alternative. Testing uses the FDA-approved BD Onclarity HPV assay, which detects 14 high-risk HPV genotypes and, with extended genotyping, reports six of them individually along with pooled groups. That gives richer risk stratification than HPV 16 and 18 alone.
For a health plan, the question is always whether a screening actually closes the gap. It does. NCQA has confirmed that HPV testing closes the Cervical Cancer Screening gap whether the sample is collected at home or in a clinic. A self-collected result counts, and with audit-ready documentation behind it.
The timing matters. The FDA cleared at-home HPV self-collection in 2026, and federal coverage requirements take effect in 2027. Plans that move now can be live for measurement year 2026 and ahead of the coverage shift, rather than scrambling to catch up.
At SNT Biotech, at-home HPV self-collection runs on one fully integrated platform and our own accredited lab, from member outreach through audit-ready reporting. It is the difference between hoping members come in and meeting them where they already are.
See how SNT Biotech brings at-home HPV self-collection to your members.